JAKAVI 5mg Tableta Melnkalne - horvātu - CInMED-Institut za ljekove i medicinska sredstva Crne Gore

jakavi 5mg tableta

"novartis pharma services ag" dio stranog druŠtva podgorica - ruksolitinib - tableta - 5mg

JAKAVI 20mg Tableta Melnkalne - horvātu - CInMED-Institut za ljekove i medicinska sredstva Crne Gore

jakavi 20mg tableta

"novartis pharma services ag" dio stranog druŠtva podgorica - ruksolitinib - tableta - 20mg

Inrebic Eiropas Savienība - horvātu - EMA (European Medicines Agency)

inrebic

bristol myers squibb pharma eeig - fedratinib dihydrochloride monohydrate - myeloproliferative disorders; primary myelofibrosis - antineoplastična sredstva - inrebic is indicated for the treatment of disease-related splenomegaly or symptoms in adult patients with primary myelofibrosis, post polycythaemia vera myelofibrosis or post essential thrombocythaemia myelofibrosis who are janus associated kinase (jak) inhibitor naïve or have been treated with ruxolitinib.

Yescarta Eiropas Savienība - horvātu - EMA (European Medicines Agency)

yescarta

kite pharma eu b.v. - axicabtagene ciloleucel - lymphoma, follicular; lymphoma, large b-cell, diffuse - antineoplastična sredstva - yescarta is indicated for the treatment of adult patients with diffuse large b cell lymphoma (dlbcl) and high-grade b-cell lymphoma (hgbl) that relapses within 12 months from completion of, or is refractory to, first-line chemoimmunotherapy. yescarta is indicated for the treatment of adult patients with relapsed or refractory (r/r) dlbcl and primary mediastinal large b cell lymphoma (pmbcl), after two or more lines of systemic therapy. yescarta is indicated for the treatment of adult patients with r/r follicular lymphoma (fl) after three or more lines of systemic therapy.